137 related articles for article (PubMed ID: 38147724)
1. Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma.
Zhang L; Wu J; Yin WW; Hu J; Liao L; Ma J; Xu Z; Wu S
Pathol Res Pract; 2024 Jan; 253():155048. PubMed ID: 38147724
[TBL] [Abstract][Full Text] [Related]
2. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
4. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
5. HIF-1α promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment.
Fu R; Du W; Ding Z; Wang Y; Li Y; Zhu J; Zeng Y; Zheng Y; Liu Z; Huang JA
Cell Death Dis; 2021 Apr; 12(4):394. PubMed ID: 33850110
[TBL] [Abstract][Full Text] [Related]
6. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
7. Vasculogenic mimicry score identifies the prognosis and immune landscape of lung adenocarcinoma.
Yang W; Li Z; Wang W; Wu J; Li J; Huang X; Zhang X; Ye X
Front Genet; 2023; 14():1206141. PubMed ID: 37351348
[No Abstract] [Full Text] [Related]
8. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
9. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
10. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
12. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
[TBL] [Abstract][Full Text] [Related]
13. A novel methionine metabolism-related signature predicts prognosis and immunotherapy response in lung adenocarcinoma.
Chang QH; Zhang YC; Zhang DY; Mao T; Chang R; Wang N; Ye Y; Xu ZJ
Aging (Albany NY); 2023 May; 15(9):3498-3523. PubMed ID: 37179124
[TBL] [Abstract][Full Text] [Related]
14. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma.
Nguyen TT; Lee HS; Burt BM; Wu J; Zhang J; Amos CI; Cheng C
Genome Med; 2022 Jan; 14(1):5. PubMed ID: 35016696
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
16. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
18. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
[TBL] [Abstract][Full Text] [Related]
19. Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Zeng L; Liang L; Fang X; Xiang S; Dai C; Zheng T; Li T; Feng Z
Funct Integr Genomics; 2023 Jul; 23(3):221. PubMed ID: 37400733
[TBL] [Abstract][Full Text] [Related]
20. A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Ou W; Wang SY
Front Immunol; 2023; 14():1147528. PubMed ID: 37033934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
